The Long COVID Treatment Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Long COVID
Interventions
DRUG

Tirzepatide

The treatment group will receive the study medication (tirzepatide) for a 12 month period starting with a 2.5mg dose once a week.

DRUG

Placebo

Participants in the control group will receive a placebo instead of active study medication for a 12 month period.

All Listed Sponsors
collaborator

Schmidt Initiative for Long COVID

UNKNOWN

lead

Scripps Translational Science Institute

OTHER

NCT07128082 - The Long COVID Treatment Trial | Biotech Hunter | Biotech Hunter